Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

CCL genes in multiple sclerosis and systemic lupus erythematosus.
World Congress of Neurology (WCN) 2015
Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: A brief overview.
FOCIS Advanced Course in Basic and Clinical Immunology
8th Annual Symposium on Glial-Neuronal Interactions
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.
Tizanidine: Can Buy Uk
Long-term impact of interferon or Glatiramer acetate in multiple sclerosis: A systematic review and meta-analysis.
Unique association of Waldenström macroglobulinemia with optic neuritis and monoclonal T cell expansion.
Biogen Idec receives notification of PDUFA date extension
Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis.
Extraocular Source of Oligodendrocytes Contribute to Retinal Myelination and Optokinetic Responses in Zebrafish.
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Anti-inflammatory dimethylfumarate: a potential new therapy for asthma?
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression.
Genzyme’s once-daily, oral AUBAGIO® (teriflunomide) approved in Argentina for the treatment of relapsing multiple sclerosis
Neuromyelitis optica spectrum disorder (NMOSD): A new concept.
Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study.
Sleep and Cognitive Function in Multiple Sclerosis.
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Teriflunomide attenuates immunopathological changes in the dark agouti rat model of experimental autoimmune encephalomyelitis.
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
Decision making under uncertainty, therapeutic inertia, and physicians' risk preferences in the management of multiple sclerosis (DIScUTIR MS).
American Academy of Neurology Annual Meeting

Pages